An EvoNexus Incubator Company
GlyTR Therapeutics has developed a breakthrough patented, novel immunotherapy technology which unleashes the power of the immune system to kill cancer in a highly targeted manner. The technology provides significant advantages over other types of therapies in that it works on multiple types of cancers including blood and solid tumors and has the potential to become an entirely new class of immunotherapeutic drugs. GlyTR’s experienced team of UCI scientists and serial entrepreneurs are dedicated to this ambitious goal of curing cancer.
To learn more visit: http://www.glytrtherapeutics.com/